1. A pharma stepwise approach to the evaluation of Nitrosamines in drug products: regulatory scenario and the role of in silico approaches. (September 2021) Authors: Zucchi, S.; Pavan, M.; Mastrocola, E.; Bassan, A.; Durando, L.; Ragni, L. Journal: Toxicology letters Issue: Volume 350(2021)Supplement Page Start: S217 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Characterization and quantification of genotoxic impurities complying with ICH M7: A pharma perspective. (16th October 2015) Authors: Landolfi, C.; Devastato, C.; Corradin, M.; Durando, L.; Ombrato, R.; Silvestri, L.; Pavan, M.; Fioravanzo, E.; Tongiani, S. Journal: Toxicology letters Issue: Volume 238(2015)Supplement Page Start: S363 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Ocular effects in rat after the peri-natal administration of bindarit, a MCP-1/CCL2 chemokine inhibitor. (16th October 2015) Authors: Devastato, C.; Landolfi, C.; Durando, L.; La Porta, D.; Guglielmotti, A.; Nyska, A.; Giavini, E.; Campana, A.; Tongiani, S. Journal: Toxicology letters Issue: Volume 238(2015)Supplement Page Start: S263 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗